This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
3fq9
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
==Design of an insulin analog with enhanced receptor-binding selectivity. Rationale, structure, and therapeutic implications== | ==Design of an insulin analog with enhanced receptor-binding selectivity. Rationale, structure, and therapeutic implications== | ||
| - | <StructureSection load='3fq9' size='340' side='right' caption='[[3fq9]], [[Resolution|resolution]] 1.35Å' scene=''> | + | <StructureSection load='3fq9' size='340' side='right'caption='[[3fq9]], [[Resolution|resolution]] 1.35Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[3fq9]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3FQ9 OCA]. For a <b>guided tour on the structure components</b> use [http:// | + | <table><tr><td colspan='2'>[[3fq9]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3FQ9 OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=3FQ9 FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> |
<tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=DAB:2,4-DIAMINOBUTYRIC+ACID'>DAB</scene>, <scene name='pdbligand=DAL:D-ALANINE'>DAL</scene></td></tr> | <tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=DAB:2,4-DIAMINOBUTYRIC+ACID'>DAB</scene>, <scene name='pdbligand=DAL:D-ALANINE'>DAL</scene></td></tr> | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4ins|4ins]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4ins|4ins]]</td></tr> | ||
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http:// | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=3fq9 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3fq9 OCA], [http://pdbe.org/3fq9 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=3fq9 RCSB], [http://www.ebi.ac.uk/pdbsum/3fq9 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=3fq9 ProSAT]</span></td></tr> |
</table> | </table> | ||
== Disease == | == Disease == | ||
| Line 34: | Line 34: | ||
==See Also== | ==See Also== | ||
| - | *[[ | + | *[[Insulin 3D Structures|Insulin 3D Structures]] |
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
| + | [[Category: Large Structures]] | ||
[[Category: Katsoyannis, P]] | [[Category: Katsoyannis, P]] | ||
[[Category: Phillips, N]] | [[Category: Phillips, N]] | ||
Revision as of 10:31, 9 September 2020
Design of an insulin analog with enhanced receptor-binding selectivity. Rationale, structure, and therapeutic implications
| |||||||||||
Categories: Large Structures | Katsoyannis, P | Phillips, N | Wan, Z L | Weiss, M A | Whittaker, J | Whittaker, L | Xu, B | Zhao, M | Carbohydrate metabolism | Cleavage on pair of basic residue | Diabetes mellitus | Disease mutation | Glucose metabolism | Hormone | Insulin design | Pharmaceutical | Rational | Receptor-binding | Secreted | Therapeutic implication

